Home >
FEATURED BLOGS
Apr 17, 2018
Clinical trials are the pathway to better treatments, better outcomes, and a future without cancer. We, as investigators, need to believe in them, and be willing to offer them to all patients who are...
Apr 06, 2018
Our vice president of Clinical Affairs breaks down the reporting changes you need to understand and address to avoid potential financial penalties in 2020.
Apr 06, 2018
Dr. Barbara K. Rimer explains that actions recently highlighted by the President’s Cancer Panel are aligned with ASCO’s recommendation that patients be informed about the costs of care as part of the...
Apr 02, 2018
It is important to recognize that some of our patients lead chaotic lives. We need to be careful of judging them and labeling them as non-compliant. They are usually just trying their best under...
Mar 22, 2018
Dr. Raj Mohan considers the concept of trust, and notes that what many patients will remember is how you made them feel comfortable as a human being, understood them, and stayed with them through...
Mar 14, 2018
If we want our patients to have the best possible health outcomes, we need to make sure that their caregivers are also being cared for.
Mar 13, 2018
When I was first asked if I would chair the Cancer Control for Primary Care Course in Bhutan, I immediately exclaimed yes! And then I sheepishly went to look up where exactly Bhutan was on a map.

Advertisement

Latest Comments & Discussions


Apar Kishor Ganti, MD
Apr 20, 2018
Course Faculty Response Similar to the experience with EGFR TKIs, most patients develop resistance to ALK TKIs, especially crizotinib,...

Lynette M. Sholl, MD
Apr 20, 2018
Course Faculty Response The mechanisms responsible for resistance in the setting of ALK-targeted therapy are diverse and including “on-...

Anis Toumeh, MD
Apr 16, 2018
I believe that, whenever possible, rebiopsy at progression should be standard for those progressing on ALK inhibitors. This helps...

Joel M. Schindler, PhD
Apr 16, 2018
Our organization has actually conducted research with cancer patients on their perceptions of drug costs, the risk of not being compliant...

ASCO University
Apr 16, 2018
Discussion Questions 1. What is the role of biopsy at progression? 2. What is the optimal choice of second-line therapy following...

Pages

Most Read

Resilience is an individual factor that affects your risk of burnout, and something you can improve for yourself by learning and practicing these specific resiliency skills.
It is important to recognize that some of our patients lead chaotic lives. We need to be careful of judging them and labeling them as non-compliant. They are usually just trying their best under difficult or even impossible situations.
Dr. Barbara K. Rimer explains that actions recently highlighted by the President’s Cancer Panel are aligned with ASCO’s recommendation that patients be informed about the costs of care as part of the treatment decision-making process.
When I was first asked if I would chair the Cancer Control for Primary Care Course in Bhutan, I immediately exclaimed yes! And then I sheepishly went to look up where exactly Bhutan was on a map.
A trial of aqueous lidocaine to manage painful intercourse for breast cancer survivors was a small study with a great magnitude of benefit. Do we need to wait for more data, or can we start applying these findings for our patients today?

Tweets from ASCO

Tweets from Oncology Community